Thyrotropin receptor mutations as a tool to understand thyrotropin receptor action

Journal of Molecular Medicine

Volumn 79, Issue 12, 2001, Pages 707-721

  Wonerow, P ^a   Neumann, S ^a   Gudermann, T ^b   Paschke, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Mutations; Site directed mutagenesis; Structure function relationships; Thyrotropin receptor

Indexed keywords

CYSTEINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR;

AMINO ACID SEQUENCE; BINDING AFFINITY; BINDING SITE; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERTHYROIDISM; IN VITRO STUDY; MOLECULAR INTERACTION; MUTATION; NONHUMAN; PROTEIN DOMAIN; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

ANIMALS; BINDING SITES; GTP-BINDING PROTEINS; HUMANS; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FSH; RECEPTORS, LH; RECEPTORS, THYROTROPIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; THYROTROPIN;

EID: 0035663195     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090100279     Document Type: Review

References (165)

1. Isolation, sequence analysis, and intron-exon arrangement of the gene encoding bovine rhodopsin
2. Molecular architecture of G protein-coupled receptors
3. The thyrotropin receptor and the regulation of thyrocyte function and growth
4. Receptors and G proteins as primary components of transmembrane signal transduction. I. G-protein-coupled receptors: Structure and function
5. Characterization of the thyroid-stimulating hormone receptor
6. The thyrotropin receptor 25 years after its discovery: New insight after its molecular cloning
7. Cloning and sequencing of porcine LH-hCG receptor cDNA: Variants lacking transmembrane domain
8. Cloning, chromosomal assignment, and regulation of the rat thyrotropin receptor: Expression of the gene is regulated by thyrotropin, agents that increase cAMP levels, and thyroid autoantibodies
9. Isolation of TSH and LH/CG receptor cDNAs from human thyroid: Regulation by tissue specific splicing
10. Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: Evidence for binding of autoantibodies
11. Cloning, sequencing and expression of human TSH receptor
12. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor
13. Molecular cloning of the thyrotropin receptor
14. Assignment of the human thyroid stimulating hormone receptor (TSHR) gene to chromosome 14q31
15. Human thyroid-stimulating hormone: Structure-function analysis
16. LH and TSH receptors. A new family of G protein-coupled receptors
17. Sequence alignment of the G-protein coupled receptor superfamily
18. Amino-terminal leucine-rich repeats in gonadotropin receptors determine hormone selectivity
19. Composite structure of the human thyrotropin receptor gene
20. Modeling of the three-dimensional structure of proteins with the typical leu-cine-rich repeats
21. Mutational analyses of the extracellular domain of the full-length lutro-pin/choriogonadotropin receptor suggest leucine-rich repeats 1-6 are involved in hormone binding
22. The crystal structure of rna1p: A new fold for a GTPase-activating protein
23. Crystal structure of porcine ri-bonuclease inhibitor, a protein with leucine-rich repeats
24. The leucine-rich repeat: A versatile binding motif
25. Human follicle-stimulating hormone structure-activity relationships
26. Novel insights into the molecular mechanisms of human thyrotropin action: Structural, physiological, and therapeutic implications for the glycoprotein hormone family
27. An insertion in the human thyrotropin receptor critical for high affinity hormone binding
28. Role of N-terminal region of the thyrotropin (TSH) receptor in signal trans-duction for TSH or thyroid stimulating antibody
29. Thyrotrophin receptor blocking antibodies: Incidence, characterization and in-vitro synthesis
30. Autoantibodies to the thyrotropin receptor
31. Site-directed mutagenesis of a portion of the extracellular domain of the rat thyrotropin receptor important in autoimmune thyroid disease and nonhomologous with gonadotropin receptors. Relationship of functional and immunogenic domains
32. Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors
33. The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies
34. Epitopes for thyroid-stimulating antibodies in Graves' sera: A possible link of heterogeneity to differences in response to antithyroid drug treatment
35. The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies
36. Further characterization of a high affinity thyrotropin binding site on the rat thyrotropin receptor which is an epitope for blocking antibodies from idiopathic myxedema patients but not thyroid stimulating antibodies from Graves' patients
37. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3′,5′- cyclic adenosine mono-phosphate signal generation
38. Identification of thyroid-stimulating antibody-specific interaction sites in the N-terminal region of the thyrotropin receptor
39. Constitutive activation of the thyro-tropin receptor by mutating CYS-636 in the sixth transmem-brane segment
40. Thyroid stimulatory autoan-tibodies in different patients with autoimmune thyroid disease do not all recognize the same components of the human thyro-tropin receptor: Selective role of receptor amino acids Ser25-Glu30
41. Immunoglob-ulins from Graves' disease patients interact with different sites on TSH receptor/LH-CG receptor chimeras than either TSH or immunoglobulins from idiopathic myxedema patients
42. Epitopes for thyroid stimulating and blocking autoantibodies on the extracellular domain of the human thyrotropin receptor
43. Dual mechanism of perturbation of thyrotropin-mediated activation of thyroid cells by antibodies to the thyrotropin receptor (TSHR) and TSHR-derived peptides
44. Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxedema, who have blocking TSHR antibodies
45. Photoaffinity labelling of the TSH receptor on FRTL5 cells
46. A new structural model for the thyrotro-pin (TSH) receptor, as determined by covalent cross-linking of TSH to the recombinant receptor in intact cells: Evidence for a single polypeptide chain
47. Specific antibody to the thyrotropin receptor identifies multiple receptor forms in membranes of cells transfected with wild-type receptor complementary deoxyribonucleic acid: Characterization of their relevance to receptor synthesis, processing, structure and function
48. Multimeric complex formation by the thyrotropin receptor in solubilized thyroid membranes
49. Two-subunit structure of the human thyrotropin receptor
50. Processing of the precursors of the human thyroid-stimulating hormone receptor in various eukaryotic cells (human thyrocytes, transfec-ted L cells and baculovirus-infected insect cells)
51. Western blot analysis of thyrotropin receptor expression in human thyroid tumours and correlation with TSH-binding
52. The TSH receptor: Structure and interaction with autoantibodies in thyroid disease
53. Analysis of thyrotropin receptors by photoaffinity labelling. Orientation of receptor subunits in the cell membrane
54. Evidence that the thy-rotropin receptor ectodomain contains not one, but two, cleavage sites
55. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain
56. Is receptor cleavage into two subunits necessary for thyrotropin action?
57. On the functional importance of thyrotropin receptor intramolecular cleavage
58. Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function
59. Thyrotropin effects on thyroid cells in culture: Effects of trypsin on the thyrotropin receptor and on thyrotropin-mediated cyclic 3′,5′-cAMP changes
60. Covalent cross-linking of thyrotropin to thyroid plasma membrane receptors: Subunit composition of the thyrotropin receptor
61. Extracellular domain chimeras of the TSH and LH/CG receptors reveal the mid-region (amino acids 171-260) to play a vital role in high affinity TSH binding
62. Eleven amino acids (Lys-201 to Lys-211) and 9 amino acids (Gly-222 to Leu-230) in the human thyro-tropin receptor are involved in ligand binding
63. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin
64. Identification of ion-izable amino acid residues on the extracellular domain of the lutropin receptor involved in ligand binding
65. Chimeric studies of the extracellular domain of the rat thyrotropin (TSH) receptor: Amino acids (268-304) in the TSH receptor are involved in ligand high affinity binding, but not in TSH receptor-specific signal transduction
66. Further studies of amino acids (268-304) in thyrotropin (TSH)-lutropin/chorionic gonadotropin (LH/CG) receptor chimeras: Cysteine-301 is important in TSH binding and receptor tertiary structure
67. Role of cys-teine residues in the extracellular domain and exoplasmic loops of the transmembrane domain of the TSH receptor: Effect of mutation to serine on TSH receptor activity and response to thyroid stimulating autoantibodies
68. Role of the carboxyl-terminal half of the extracellular domain of the human thyrotropin receptor in signal transduction
69. Studies on the role of amino acids 38-45 in the expression of a functional thyrotropin receptor
70. Characterization of soluble, disulfide bond-stabilized, prokaryotic-ally expressed human thyrotropin receptor ectodomain
71. Characterization of the extracellular region of the human thyrotrophin receptor expressed as a recombinant protein
72. Critical relationship between autoantibody recognition and thyrotropin receptor maturation as reflected in the acquisition of complex carbohydrate
73. A full biological response to autoantibodies in graves' disease requires a disulfide-bonded loop in the thyro-tropin receptor n terminus homologous to a laminin epidermal growth factor-like domain
74. Four families with loss of function mutations of the thyrotropin receptor
75. Localization and synthesis of the hormone-binding regions of the human thyro-tropin receptor
76. Structure-function studies of the human thyrotropin receptor. Inhibition of binding labeled thyrotropin (TSH) by synthetic human TSH receptor peptides
77. Thyrotro-pin (TSH) interacts with multiple discrete regions of the TSH receptor: Polyclonal rabbit antibodies to one or more of these regions can inhibit TSH binding and function
78. Thyrotropin cross-links to the thyrotropin receptor through both the alpha and beta subunits
79. Characteristics of a solubilized thyrotropin receptor from bovine thyroid plasma membranes
80. Stable expression of the human TSH receptor in CHO cells and characterization of differentially expressing clones
81. Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): A new bioassay for human thyrotropin
82. Interaction of thy-rotropin and thyroid-stimulating antibodies with recombinant extracellular region of human TSH receptor
83. Binding of antithyrotropin receptor autoantibodies in Graves' disease serum to nascent, in vitro translated thyrotropin receptor: Ability to map epitopes recognized by antibodies
84. Thyrotropin (TSH) receptor autoantibodies do not appear to bind to the TSH receptor produced in an in vitro transcription/translation system
85. Overexpression of the extracellular domain of the thyrotrophin receptor in bacteria; production of thyrotrophin-binding inhibiting immunoglobulins
86. Expression of a human thyrotrophin receptor fragment in Escher-ichia coli and its interaction with the hormone and autoanti-bodies from patients with Graves' disease
87. Prokaryotic expression of the thyrotropin receptor and identification of an immunogenic region of the protein using synthetic peptides
88. The thyrotrophin hormone receptor of Graves' disease: Overexpression of the extracellular domain in insect cells using recombinant baculovirus, immunoaffinity purification and analysis of autoantibody binding
89. Induction of TSH binding inhibitory im-munoglobulins with the extracellular domain of human thyro-tropin receptor produced using baculovirus expression system
90. Expression of the extra-cellular domain of the thyrotropin receptor in the baculovirus system using a promoter active earlier than the polyhedrin promoter. Implications for the expression of functional highly glycosylated proteins
91. A recombinant extracellular domain of the thyro-tropin (TSH) receptor binds TSH in the absence of membranes
92. Engineering the human thyrotropin receptor ectodo-main from a non-secreted form to a secreted, highly immuno-reactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera
93. Derivation of functional antagonists using N-terminal extra-cellular domain of gonadotropin and thyrotropin receptors
94. High-affinity binding of thyrotropin to the extracellular domain of its receptor transfected in Chinese hamster ovary cells
95. Production of the thyrotro-phin receptor extracellular domain as a glycosylphosphatidyl-inositol-anchored membrane protein and its interaction with thyrotrophin and autoantibodies
96. Disruption of the first extracellular loop of thyrotropin receptor prevents li-gand binding
97. The functional significance of the second extracellular loop of thyrotropin receptor in thyrotropin- and thyroid stimulating antibody-dependent signal transduction
98. The thyrotropin (TSH) receptor transmembrane domain mutation (Pro556-Leu) in the hypothyroid hyt/hyt mouse results in plasma membrane targeting but defective TSH binding
99. Identification of a point mutation in the thyrotropin receptor of the hyt/hyt hypothy-roid mouse
100. Two novel mutations in the thyrotropin (TSH) receptor gene in a child with resistance to TSH
101. Brief report: Resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene
102. Mutations of the human thy-rotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism
103. Structure-function relationships of two loss-of-function mutations of the thyrotropin receptor gene
104. Constitutive activation of the thyrotropin receptor by deletion of a portion of the extracellular domain
105. Enhanced cAMP accumulation by the human thyrotropin receptor variant with the Pro52Thr substitution in the extracellular domain
106. Functional characteristics of a variant thyrotropin receptor
107. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (ser-ine281->isoleucine) in the extracellular domain of the thyro-tropin receptor
108. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain
109. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas
110. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules
111. Severe congenital hyper-thyroidism caused by a germ-line neo mutation in the extra-cellular portion of the thyrotropin receptor
112. Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region
113. Specific activation of the thy-rotropin receptor by trypsin
114. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: Implications for hormone-receptor interaction and antagonist design
115. Cloning and sequencing of human LH/hCG receptor cDNA
116. The follicle-stimulating hormone receptor: Biochemistry, molecular biology, physiology, and pathophysiology
117. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors
118. The human thyrotropin receptor activates G-proteins Gs and Gq/11
119. The human thyrotro-pin receptor: A heptahelical receptor capable of stimulating members of all four G protein families
120. Thyrotropin activates both the cyclic AMP and the PIP2 cascades in CHO cells expressing the human cDNA of TSH receptor
121. In Chinese hamster ovary K1 cells dog and human thyrotropin receptors activate both the cyclic AMP and the phosphatidylinositol 4:5-bisphosphate cascades in the presence of thyrotropin and the cyclic AMP cascade in its absence
122. Multiple G-protein coupling of the dog thyrotropin receptor
123. Point mutations of the thyrotropin receptor determining structural requirements for its ability to bind thyrotropin and to stimulate adenylate cyclase activity
124. Aspartate-474 in the first exoplasmic loop of the thy-rotropin receptor is crucial for receptor activation
125. The third exoplasmic loop of the thyrotropin receptor is partially involved in signal transduc-tion
126. Somatic mutations causing constitutive activity of the TSH receptor are the major cause of hyper-functional thyroid adenomas: Identification of additional mutations activating both the cAMP and inositolphosphate-Ca++ cascades
127. Hy-perfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma
128. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia
129. Differential effects of NaCl concentration on the constitutive activity of the thy-rotropin and the luteinizing hormone/chorionic gonadotropin receptors
130. Two autonomous nodules of a patient with multinodular goiter harbor different activating mutations of the thyrotropin receptor gene
131. Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism
132. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters
133. Constitutive activation of cyclic AMP but not phosphatidylinositol signaling caused by mutations in the 6th transmembrane helix of the human thyrotropin receptor
134. Identification and functional characterization of two new somatic mutations causing constitutive activation of the TSH receptor in hyperfunctioning autonomous adenomas of the thyroid
135. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy
136. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas
137. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas
138. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: Low prevalence of mutations predicts infrequent involvement in malignant transformation
139. Germline mutations in the thyrotropin receptor gene cause non autoimmune autosomal dominant hy-perthyroidism
140. Variable phenotype associated with Ser505Asn-activating thyrotropin-receptor germline mutation
141. Sporadic congenital hy-perthyroidism due to a spontaneous germline mutation in the thyrotropin receptor gene
142. Substitutions of tyrosine 601 in the human thyrotropin receptor result in increase or loss of basal activation of the cyclic adenosine monophosphate pathway and disrupt coupling to Gq/11
143. A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthy-roidism
144. Evidence for the direct involvement of transmembrane region 6 of the lutropin/chorio-gonadotropin receptor in activating Gs
145. A model of the lutro-pin/choriogonadotropin receptor: Insights into the structural and functional effects of constitutively activating mutations
146. A free carboxylate oxygen in the side chain of position 674 in trans-membrane domain 7 is necessary for TSH receptor activation
147. Role of the third intracellular loop for the activation of gonadotropin receptors
148. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
149. Genetic alterations in thyroid hyper-functioning adenomas
150. G-protein-coupled receptor genes as protooncogenes: Constitutively activating mutation of the a1B-adrenergic receptor enhances mitogenesis and tumorigenicity
151. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation
152. Functional analysis of the cytoplasmic domains of the human thyrotropin receptor by site-directed mutagenesis
153. Signal transduction by the human thyro-tropin receptor: Studies on the role of individual amino acid residues in the carboxyl terminal region of the third cytoplasmic loop
154. Deletions in the third intracellular loop of the thyro-tropin receptor. A new mechanism for constitutive activation
155. Shortening the 3rd intracellular loop leads to TSHR activation
156. Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis
157. An anionic residue at position 564 is important for maintaining the inactive conformation of the human lutropin/choriogonadotropin receptor
158. Requirement of specific intrahelical interactions for stabilizing the inactive conformation of glycoprotein hormone receptors
159. Mutation of alanine 623 in the third cytoplasmic loop of the rat thyrotropin (TSH) receptor results in a loss in the phosphoinositide but not cAMP signal induced by TSH and receptor autoantibodies
160. A conserved tyrosine residue (Y601) in transmembrane domain 5 of the human thyro-tropin receptor serves as a molecular switch to determine G-protein coupling
161. Mechanisms of shedding of a soluble form of the TSH receptor
162. Crystal structure of rhodopsin: A G-protein-coupled receptor
163. Purification and structural analysis of a soluble human chorionogonadotropin hormone-receptor complex
164. Hormone induced conformational change of the purified soluble hormone binding domain of follitropin receptor complexed with single chain follitropin
165. The TSH receptor mutation database